. Author manuscript; available in PMC: 2014 Oct 22.

Published in final edited form as: J Am Coll Cardiol. 2013 Dec 4;63(9):891–900. doi: 10.1016/j.jacc.2013.11.013

Table 1.

Event Rates and HRs and 95% CIs for Bleeding Events

	Events (Rate)		HR (95% CI)	p Value
	Rivaroxaban (n = 7,111)	Warfarin (n = 7,125)	HR (95% CI)	p Value
Principal safety endpoint	1,475 (14.91)	1,449 (14.52)	1.03 (0.96–1.11)	0.442

Major	395 (3.60)	386 (3.45)	1.04 (0.90–1.20)	0.576
Hemoglobin/hematocrit drop	305 (2.77)	254 (2.26)	1.22 (1.03–1.44)	0.019
Transfusion	183 (1.65)	149 (1.32)	1.25 (1.01–1.55)	0.044
Critical organ bleeding	91 (0.82)	133 (1.18)	0.69 (0.53–0.91)	0.007
Death	27 (0.24)	55 (0.48)	0.50 (0.31–0.79)	0.003

Nonmajor clinically relevant	1,185 (11.80)	1,151 (11.37)	1.04 (0.96–1.13)	0.345

Minimal	258 (2.35)	226 (2.03)	1.16 (0.97–1.39)	0.102

Event rates/100 patient-years.

CI = confidence interval; HR = hazard ratio.